scholarly journals Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis

2012 ◽  
Vol 27 (9) ◽  
pp. 3552-3559 ◽  
Author(s):  
Xiao-wei Yang ◽  
Ying Tan ◽  
Feng Yu ◽  
Ming-hui Zhao
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Renal Prognosis ◽  
Dsdna Antibodies

Clinical and immunological characteristics of 150 systemic lupus erythematosus patients in Jamaica: a comparative analysis

Lupus ◽  
2017 ◽  
Vol 26 (13) ◽  
pp. 1448-1456 ◽  
Author(s):  
K C Maloney ◽  
T S Ferguson ◽  
H D Stewart ◽  
A A Myers ◽  
K De Ceulaer
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Disease Activity ◽  
Renal Biopsy ◽  
Diagnostic Criteria ◽  
Lupus Erythematosus ◽  
Antinuclear Antibodies ◽  
Damage Index ◽  
Systemic Lupus ◽  
Dsdna Antibodies

Background Epidemiological studies in systemic lupus erythematosus have been reported in the literature in many countries and ethnic groups. Although systemic lupus erythematosus in Jamaica has been described in the past, there has not been a detailed evaluation of systemic lupus erythematosus patients in urban Jamaica, a largely Afro-Caribbean population. The goal of this study was to describe the clinical features, particularly disease activity, damage index and immunological features, of 150 systemic lupus erythematosus subjects. Methods 150 adult patients (≥18 years) followed in rheumatology clinic at a tertiary rheumatology hospital centre (one of two of the major public referral centres in Jamaica) and the private rheumatology offices in urban Jamaica who fulfilled Systemic Lupus International Collaborating Clinics (SLICC) criteria were included. Data were collected by detailed clinical interview and examination and laboratory investigations. Hence demographics, SLICC criteria, immunological profile, systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) and SLICC/American College of Rheumatology (ACR) damage index (SDI) were documented. Results Of the 150 patients, 145 (96.7%) were female and five (3.3%) were male. The mean age at systemic lupus erythematosus onset was 33.2 ± 10.9. Mean disease duration was 11.3 ± 8.6 years. The most prevalent clinical SLICC criteria were musculoskeletal, with 141 (94%) of subjects experiencing arthralgia/arthritis, followed by mucocutaneous manifestations of alopecia 103 (68.7%) and malar rash 46 (30.7%), discoid rash 45 (30%) and photosensitivity 40 (26.7%). Lupus nephritis (biopsy proven) occurred in 42 (28%) subjects and 25 (16.7%) met SLICC diagnostic criteria with only positive antinuclear antibodies/dsDNA antibodies and lupus nephritis on renal biopsy. The most common laboratory SLICC criteria were positive antinuclear antibodies 136 (90.7%) followed by anti-dsDNA antibodies 95 (63.3%) and low complement (C3) levels 38 (25.3%). Twenty-seven (18%) met SLICC diagnostic criteria with only positive antinuclear antibodies/anti-dsDNA antibodies and lupus nephritis on renal biopsy. Mean SLEDAI score was 6.9 ± 5.1 with a range of 0–32. Organ damage occurred in 129 (86%) patients; mean SDI was 2.4 ± 1.8, with a range of 0–9. Conclusion These results are similar to the clinical manifestations reported in other Afro-Caribbean populations; however, distinct differences exist with respect to organ involvement and damage, particularly with respect to renal involvement, which appears to be reduced in our participants.

Wire-loop lesion is associated with serological immune abnormality, but not renal prognosis, in lupus nephritis

Lupus ◽  
2020 ◽  
Vol 29 (4) ◽  
pp. 407-412
Author(s):  
T Zoshima ◽  
S Hara ◽  
I Mizushima ◽  
R Nishioka ◽  
K Ito ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Lupus Nephritis ◽  
Renal Biopsy ◽  
Class Iii ◽  
Tubular Atrophy ◽  
Wire Loop ◽  
Factors Associated ◽  
Clinicopathological Findings ◽  
Renal Prognosis ◽  
Dsdna Antibodies

Background Wire-loop lesion (WL) is one of the active lesions of lupus nephritis (LN). However, few reports have focused on the clinicopathological relationships of WL to serological immune abnormality and renal prognosis. Methods We enrolled 126 Japanese LN patients subjected to renal biopsy in 11 hospitals from 2000 to 2018. In patients with class III or IV of the International Society of Nephrology/Renal Pathology Society classification, we retrospectively compared clinicopathological findings between those with WL (WL+ group) and without WL (WL– group) to detect factors associated with WL. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate of <60 mL/min/1.73m2 for more than three months. We also compared these findings between those with CKD (CKD+ group) and without CKD (CKD– group) at the last visit to investigate factors associated with renal prognosis. Results Of 126 patients, 100 (79.4%) were classified as class III or IV. WL was found in 36 (36.0%) of them. Although the renal function did not differ, the WL+ group had a higher titre of serum anti-dsDNA antibodies and lower serum complement 3 levels than the WL– group. Linear regression analysis revealed a significant association only between anti-dsDNA antibodies and WL (β = 0.27, 95% confidence interval (CI) 0.001–0.100, p = 0.01). Of these patients, 69 were tracked for 59.6 ± 55.1 months. Kaplan–Meier analysis showed no difference in renal prognosis between these groups. Next, the CKD+ group included 15 (22.1%) patients. They were older and had higher frequencies of hypertension and hyperuricaemia, serum creatinine (Cr) level, glomerulosclerosis, interstitial inflammation, interstitial fibrosis and tubular atrophy than the CKD– group at the time of renal biopsy. The frequency of WL was not significantly different. Cox regression analysis revealed significant associations of CKD with hypertension, hyperuricaemia, serum Cr level at the time of renal biopsy clinically and with tubular atrophy histologically. Conclusions WL was associated with serum anti-dsDNA antibodies but not with renal prognosis, suggesting that WL reflects immune abnormality but is not an independent factor predictive of renal prognosis in LN.

scholarly journals Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis

2007 ◽  
Vol 56 (6) ◽  
pp. 1894-1903 ◽  
Author(s):  
Milena Pitashny ◽  
Noa Schwartz ◽  
Xiaoping Qing ◽  
Bernard Hojaili ◽  
Cynthia Aranow ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Lipocalin 2

SAT0413 Urinary Lipocalin-2 as a Biomarker of Renal Disease Activity in Patients with Lupus Nephritis: A Prospective Study

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 808.3-809
Author(s):  
N. M. Gamal ◽  
N.M. Mustafa ◽  
E. A.M. Abda ◽  
O. Afifi ◽  
N. Fathi
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Prospective Study ◽  
Disease Activity ◽  
Lipocalin 2 ◽  
A Prospective Study

scholarly journals Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment

RMD Open ◽  
2020 ◽  
Vol 6 (2) ◽  
pp. e001257
Author(s):  
Jennifer C Davies ◽  
Angela Midgley ◽  
Emil Carlsson ◽  
Sean Donohue ◽  
Ian N Bruce ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Calcium Binding ◽  
Therapeutic Potential ◽  
Activity Index ◽  
S100 Proteins ◽  
Response To Treatment ◽  
Inflammatory Disorder ◽  
Serum And Urine

BackgroundApproximately 30% of patients with the systemic autoimmune/inflammatory disorder systemic lupus erythematosus (SLE) develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease. The Maximizing SLE Therapeutic Potential by Application of Novel and Systemic Approaches and the Engineering Consortium aims to identify indicators of treatment responses in SLE. This study tested the applicability of calcium-binding S100 proteins in serum and urine as biomarkers for disease activity and response to treatment with rituximab (RTX) in LN.MethodsS100A8/A9 and S100A12 proteins were quantified in the serum and urine of 243 patients with SLE from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR) study and 48 controls matched for age using Meso Scale Discovery’s technology to determine whether they perform as biomarkers for active LN and/or may be used to predict response to treatment with RTX. Renal disease activity and response to treatment was based on BILAG-BR scores and changes in response to treatment.ResultsSerum S100A12 (p<0.001), and serum and urine S100A8/A9 (p<0.001) levels are elevated in patients with SLE. While serum and urine S100 levels do not correlate with global disease activity (SLE Disease Activity Index), levels in urine and urine/serum ratios are elevated in patients with active LN. S100 proteins perform better as biomarkers for active LN involvement in patients with SLE who tested positive for anti-double-stranded DNA antibodies. Binary logistic regression and area under the curve analyses suggest the combination of serum S100A8/A9 and S100A12 can predict response to RTX treatment in LN after 6 months.ConclusionsFindings from this study show promise for clinical application of S100 proteins to predict active renal disease in SLE and response to treatment with RTX.

Urinary Angiotensinogen Predicts Renal Disease Activity in Lupus Nephritis

2019 ◽  
Vol 31 (17) ◽  
pp. 1289-1301
Author(s):  
Meng Shi ◽  
Weihong Luo ◽  
Xiaodan Feng ◽  
Lingwei Jin ◽  
Manqiu Yang ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Urinary Angiotensinogen

scholarly journals Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis

2009 ◽  
Vol 11 (6) ◽  
pp. R188 ◽  
Author(s):  
Christopher Sjöwall ◽  
Agneta Zickert ◽  
Thomas Skogh ◽  
Jonas Wetterö ◽  
Iva Gunnarsson
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Serum Levels ◽  
Response To Therapy ◽  
C Reactive Protein ◽  
Reactive Protein

Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis

2009 ◽  
Vol 36 (10) ◽  
pp. 2224-2230 ◽  
Author(s):  
ADNAN N. KIANI ◽  
KRISTEN JOHNSON ◽  
CATHERINE CHEN ◽  
EDWARD DIEHL ◽  
HUAIZHONG HU ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Creatinine Ratio ◽  
Longitudinal Assessment ◽  
Urine Protein ◽  
Monocyte Chemoattractant Protein 1 ◽  
Monocyte Chemoattractant ◽  
Monocyte Chemoattractant Protein

Objective.Renal biopsy is the “gold standard” to determine renal activity in systemic lupus erythematosus (SLE), but it is expensive, invasive, and carries risk. Osteoprotegerin (OPG) is produced by the heart, lungs, kidney, and bone. Monocyte chemoattractant protein-1 (MCP-1), a chemotactic cytokine, is involved in the progression of glomerular and tubulointerstitial injury. We investigated both urine OPG and MCP-1 as potential biomarkers for lupus nephritis.Methods.Our subjects, 87 patients with SLE (88% women; 48% African American, 41% Caucasian, 11% other), mean age 44 years, were followed monthly to quarterly. Urinary OPG (pg/ml) and MCP-1 (pg/ml) were measured (Luminex MAP bead assay).Results.OPG concentrations were strongly associated with global disease activity and with both renal activity on a visual analog scale (VAS) (p = 0.0006) and renal disease activity descriptors of the SELENA SLEDAI, including hematuria (p = 0.001) and a positive anti-dsDNA (p = 0.013). MCP-1 was also associated with the renal VAS (p = 0.032), renal disease activity descriptors of SELENA SLEDAI, including hematuria (p = 0.027), and with a positive anti-dsDNA (p = 0.016). We also examined the relationship between the biomarkers and having a urine protein to creatinine ratio (pr/cr) ≥ 0.5. Among patients with medium or high OPG, 46% had urine pr/cr ≥ 0.5, compared to only 23% among those with low OPG (p = 0.032). The 2 biomarkers were strongly correlated with each other (Spearman correlation coefficient 0.77, p < 0.0001).Conclusion.The lack of availability of urine biomarkers has hampered development of new therapies for lupus nephritis. Urine MCP-1 and OPG were both associated with measures of lupus renal disease activity. Medium or high levels of OPG were predictive of a urine protein/creatinine ratio of ≥ 0.5. Further study, including longitudinal assessment and correlation with concurrent renal biopsies, is necessary before this assay can be used in the routine clinic setting.

Sign in / Sign up

Export Citation Format

Share Document